

A glycoconjugate vaccine composition against Salmonella Typhi and Salmonella Paratyphi

[Click Here for Detailed EoI Document](#)

About the Technology: Vi polysaccharide purified from Citrobacter freundii chemically conjugated to the recombinant outer membrane protein (T2544) of Salmonella Typhi/Paratyphi

Technology ID: PM-TT-IM-2026-Apr-44

Lead Inventor: Dr. Santasabuj Das

Institute: ICMR - National Institute for Research in Bacterial Infections

Technology Domain: Vaccine and Therapeutics


Disease Area (Broad): Enteric infections – Typhoid and Paratyphoid fever

Need and utility of the Technology from Public health perspective:

Existing vaccines mainly target S. Typhi and offer limited or no protection against S. Paratyphi. Rising multidrug resistance increases disease burden. This vaccine addresses the unmet need for broader, durable protection in endemic regions like India.

Technology Readiness level (TRL):

TRL-4: Validated at in house laboratory



Validation Status and Study Outcome:

- Inhouse Validation –Complete
- Efficacy Outcome: Demonstrated protection against S. Typhi and S. Paratyphi. A Induced strong seroconversion, mucosal IgA response, and long-term immune memory

Market Potential: The technology has strong potential for national immunization programs and global vaccine markets.

Unmet need: High endemicity of enteric fever in Asia and absence of effective paratyphoid vaccines present a significant market gap.

Publication: NA

IP Filing: Filed (application no. 202411074276.